Impact Factor
3.70
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.83
922 total citations
h5-index
36
h5 depth signal
Cited share
75.6%
189 of 250
Total citations
922
Citation footprint
Metric signal
4.21
External metric anchor
Self-citation
9.4%
87 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
470
Netherlands
309
Germany
275
United Kingdom
245
Italy
168
Citing Fields of Research
Mitochondria
370
Lysosomal Storage Disorders
316
Congenital Disorders
219
Genetics & Genomics
210
Vitamin Metabolism
154
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
6,558
Articles tracked across the journal lifetime
Indexed publication set
250
189 cited publications
Last 12 months
162
13.5 publications/month
Open access share
66.7%
108 OA publications in the last year
Leading citing country
United States
470 citing publications
Leading citing field
Mitochondria
370 citing publications
Latest tracked publication
12 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1978-
v1n1, 1978-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lysosomal Storage Disorders
Mitochondria
Vitamin Metabolism
Genetics & Genomics
Congenital Disorders
Issuing & Sponsoring Bodies
Contributor
Society for the Study of Inborn Errors of Metabolism
Broad Categories
Metabolism
Mitochondria
Lysosomal Storage Disorders
Vitamin Metabolism
MeSH Descriptors
Metabolism, Inborn Errors
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/jimd.70259
Open DOI
Revisiting Inherited Metabolic Diseases ( IMDs ) Through the Lens of Selective Autophagy
Selective autophagy is increasingly recognized as a fundamental quality‐control mechanism that complements bulk autophagy by enabling the targeted degradation of specific intracellular cargos, including mitochondria, endoplasmic reticulu...
02
DOI 10.1002/jimd.70254
Open DOI
Tailored Amino Acid Treatment for Pediatric Patients With Mitochondrial Aminoacyl‐ tRNA Synthetase Deficiencies
Aminoacyl‐tRNA synthetases (ARSs) facilitate the loading of transfer RNAs with their cognate amino acids in the cytosol (ARS1), mitochondria (ARS2), or both (dual ARS). ARS deficiencies are clinically heterogeneous and can cause severe, ...
03
Pyruvate dehydrogenase complex (PDHc) deficiency (PDCD) is a primary mitochondrial disorder characterized by neurodevelopmental disability, altered intermediary metabolism, and early mortality. Dichloroacetate (DCA), a pyruvate analog, a...
04
DOI 10.1002/jimd.70258
Open DOI
Obituary for Prof. Marcello Giovanni
05
DOI 10.1002/jimd.70226
Open DOI
Consensus Guidelines for Diagnosis and Management of Pyruvate Dehydrogenase Complex Deficiency
Primary pyruvate dehydrogenase complex deficiency (PDCD) comprises a group of monogenic disorders caused by pathogenic variants in genes encoding subunits of, or regulatory components affecting, the pyruvate dehydrogenase complex. The cl...
06
DOI 10.1002/jimd.70252
Open DOI
Essential Oral Single Nutritional Therapy Products for Inherited Metabolic Diseases: Evidence and Consensus Assessment Using a Modified Delphi Method
Nutritional therapy is critical in managing inherited metabolic diseases (IMDs), and includes specialized diets and single nutritional therapy products (sNTPs) such as vitamins, cofactors, and amino acids. Many sNTPs function as medicine...
07
DOI 10.1002/jimd.70256
Open DOI
Congenital Disorders of Glycosylation ( CDG ): State of the Art in 2026
Congenital disorders of glycosylation (CDG) are a rapidly expanding group of inherited metabolic diseases affecting glycoconjugate glycan biosynthesis and attachment. This review provides a structured overview of major advances in human ...
08
DOI 10.1002/jimd.70206
Open DOI
Issue Information
09
DOI 10.1002/jimd.70255
Open DOI
Treatment of Fatty Acid Oxidation Disorders Today: Emerging Personalized Treatment Strategies
The first international guideline on treatment and management of long‐chain fatty acid oxidation disorders has been published and demonstrates little scientific evidence for many of the treatment decisions. However, it is a substantial a...
10
DOI 10.1002/jimd.70251
Open DOI
International Guideline on the Diagnosis, Treatment, and Monitoring of Long‐Chain Fatty Acid Oxidation Disorders ( LC ‐ FAOD )
Long‐chain fatty acid oxidation disorders (LC‐FAOD) are rare inherited defects of mitochondrial β‐oxidation that impair energy generation during fasting or metabolic stress. Clinical manifestations range from neonatal hypoketotic hypogly...
Bibliographical & Catalog Notes
Published for the Society for the Study of Inborn Errors of Metabolism.
Imprint varies.
Also available online.